CDC Notice of Intent to Sole Source for Inhalation Support / TSI MOUDI-II Instrument

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

CDC OFFICE OF ACQUISITION SERVICES

Contract Value

Not provided

Codes & Classification
Solicitation Number

75D301-26-Q-98063

NAICS

334516 - Analytical Laboratory Instrument Manufacturing

Classification Code

6640

Additional Details
Set Aside

SBA

Place of Performance

Morgantown, West Virginia, UNITED STATES

SourceSAM
Documents2
The Centers for Disease Control and Prevention (CDC), operating under the Department of Health and Human Services, has issued a Special Notice indicating its intent to award a sole-source contract for the procurement of a TSI MOUDI-II Instrument to support inhalation research activities. This acquisition will be managed by the CDC Office of Acquisition Services, with the place of performance designated as Morgantown, West Virginia. The primary objective of this procurement is to obtain a Micro Orifice Uniform-Deposit Impactor (MOUDI) instrument that meets the CDC’s stringent requirements for inhalation research. The MOUDI-II, manufactured exclusively by TSI Incorporated, is specified due to its unique capability to provide a wide range of size classification and to deposit samples uniformly—features critical for the CDC’s analytical and research needs in the field of aerosol science and inhalation exposure assessment. The instrument falls under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing) and Product Service Code 6640, reflecting its specialized application in laboratory analysis. This notice is not a solicitation for competitive quotations; rather, it serves to inform the public of the CDC’s intent to utilize simplified acquisition procedures to make a sole-source award. The CDC has determined that TSI Incorporated is the only source capable of fulfilling the technical and performance requirements necessary for this research initiative. The attached statement of work and specifications provide further detail on the required deliverables and performance criteria. Interested parties who believe they possess the capability to meet these requirements are invited to submit a capability statement for consideration. Such submissions must be received by 4:00 PM (EST) on June 17, 2026. The government will review any responses solely to determine whether a competitive procurement process is warranted. All costs associated with responding to this notice are the responsibility of the interested party, and the government is not liable for any expenses incurred. The procurement is identified as an SBA set-aside, and all correspondence, including questions and capability statements, should be directed to the Contract Specialist, Aminah A. Gary, via email at [email protected] or by phone at 404-498-3206. The notice remains active, with a formal response deadline of June 25, 2026. This opportunity is particularly relevant for contractors specializing in analytical laboratory instrument manufacturing, specifically those with expertise in aerosol measurement and inhalation research instrumentation. The CDC’s focus on sole-source justification underscores the critical nature of the technical specifications and the necessity for proven, specialized equipment to support its public health mission. For further details, including access to the statement of work and specifications, interested parties are encouraged to review the notice and attachments available at the official SAM.gov listing: https://sam.gov/opp/4a68c4237cd14593b5937820bb14cf6a/view.